StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $39.50 | $39.25 | -0.63% | 7.5M |
| 05-12 | $39.28 | $38.55 | -1.86% | 7.7M |
| 05-13 | $38.43 | $38.71 | +0.73% | 7.7M |
| 05-14 | $38.80 | $38.90 | +0.26% | 4.4M |
| 05-15 | $38.95 | $36.19 | -7.09% | 7.4M |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Medline is the largest provider of medical-surgical products and supply chain solutions in the US. The company generates over 90% of its revenue domestically and serves some of the largest US health systems. Medline offers approximately 190,000 Medline-branded products across more than 250 product families—including front-line care, surgical solutions, and laboratory and diagnostics—as well as roughly 150,000 third-party products sourced from over 1,250 vendors. The company maintains prime vendor relationships with many customers, acting as the primary consolidated logistics partner for their medical-surgical needs. Medline has significant scale, supported by more than 30 manufacturing facilities and a fleet of over 2,000 owned delivery trucks. Medline went public in December 2025.
| Metric | Q1 2026 2026-03-28 | Annual 2025 2025-12-31 | Q1 2025 2025-03-29 | Annual 2024 2024-12-31 |
|---|---|---|---|---|
Revenue | $7.35B | $28.43B | $6.64B | $25.51B |
Operating Income | $422.00M | $2.21B | $571.00M | $2.15B |
Net Income | $239.00M | $1.16B | $319.00M | $1.16B |
EPS (Diluted) | $0.16 | $-0.01 | Not available | Not available |
Total Assets | $39.01B | $38.48B | Not available | $35.98B |
Total Liabilities | $19.66B | $19.20B | Not available | $19.45B |
Cash & Equivalents | $2.24B | $1.94B | $840.00M | $199.00M |
Free Cash Flow OCF − CapEx | $316.00M | $1.30B | $584.00M | $1.42B |
Shares Outstanding | 824.84M | 810.00M | Not available | Not available |